Major depressive disorder (MDD) is a debilitating condition linked to disruptions in adult hippocampal neurogenesis, where neural stem cells fail to mature into functional neurons. This impairment, along with molecular changes in genes that regulate synaptic plasticity and cellular stress, contributes to the disorder's complex pathophysiology.
The neurogenic deficits are just one piece of a larger puzzle. Depression also involves dysfunctional emotional memory processing and widespread alterations across multiple brain regions. This article explores the multifaceted mechanisms underlying MDD, focusing on the interplay between impaired neurogenesis, memory disturbances, synaptic dysfunction, and emerging therapeutic strategies targeting these diverse pathways.
Why depression takes place
Depression arises when chronic stress, genetic predisposition, and neurobiological disruptions, such as reduced BDNF, impaired hippocampal neurogenesis, and altered neurotransmitters, impair synaptic plasticity and emotional regulation circuits. Environmental triggers, inflammation, and cognitive biases further reinforce these altered neural pathways, sustaining the depressive state.
Relationships of depression with neurogenesis
Depression is associated with impaired adult hippocampal neurogenesis. Research has shown that individuals with MDD have a higher proportion of quiescent neural stem cells and a lower proportion of neuroblasts, indicating stalled progression from stem cells to new neurons.
This disruption in the maturation process is linked to molecular alterations, including increased expression of interferon-related genes and reduced neurogenesis-related gene expression. While this impairment is a key feature, it does not definitively prove a causal relationship, as depression also involves broader hippocampal molecular changes and other brain regions.
Relationship of depression with memory loss
Memory loss in MDD is often attributed to changes in the hippocampus, a brain region crucial for memory and learning. Depression can cause neural damage that reduces grey matter volume in the hippocampus, potentially leading to memory complications.
An abnormal immune response, or neuroinflammation, is thought to disrupt the growth of new brain cells, contributing to memory impairment. Furthermore, issues with attention and concentration, common symptoms of depression, can prevent information from being stored as a memory.
Sleep problems, another frequent symptom, can further interfere with the hippocampus's ability to process and store long-term memories.
Major Depressive Disorder and Neuron Maturity
MDD is increasingly understood not simply as a chemical imbalance, but as a structural and neurodevelopmental disorder characterised by impaired adult neurogenesis and structural regression in key brain regions like the hippocampus and prefrontal cortex.
Adult hippocampal neurogenesis (AHN) occurs in the subgranular zone of the dentate gyrus, where neural stem cells proliferate, differentiate, and mature into functional granule neurons. In patients with MDD, this pipeline of neuronal maturation is severely disrupted, leading to a deficit in fully mature, integrated neurons necessary for mood regulation and cognitive flexibility.
Mechanisms of Maturation Arrest
At the cellular level, chronic stress, a primary environmental driver of depression, activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating systemic glucocorticoid levels. Prolonged exposure to high cortisol suppresses brain-derived neurotrophic factor (BDNF) expression via the TrkB signalling pathway. BDNF is critical for late-stage neuronal maturation, arborization, and dendritic spine formation. When BDNF levels fall:
- Arrested Dendritic Arborization: Immature neurons fail to extend complex dendritic trees and remain functionally isolated.
- Impaired Pattern Separation: A reduced population of mature dentate gyrus neurons compromises the brain's ability to distinguish between similar contexts, causing benign stimuli to trigger overactive fear and stress responses.
- Prefrontal Shrinkage: Loss of mature, highly connected pyramidal neurons in the prefrontal cortex reduces top-down inhibitory control over the amygdala, amplifying emotional reactivity.
Therapeutic Antidepressant Targets
Traditional monoaminergic antidepressants (SSRIs, SNRIs) and novel rapid-acting agents like ketamine exert their therapeutic effects in part by restarting neuronal maturation. Chronic SSRI treatment increases local BDNF expression, which rescues immature neurons from apoptosis and promotes their morphological integration into existing hippocampal microcircuits over a 4- to 6-week window—closely mirroring the clinical lag time of antidepressant efficacy.
Role of Negative Memories in Depression
A defining feature of MDD is negative cognitive bias: the systematic tendency to selectively encode, consolidate, and recall distressing or threat-related information while ignoring positive experiences. This bias creates a self-reinforcing loop where intrusive negative memories dictate mood state, and depressed mood state enhances the accessibility of negative memories (mood-congruent memory recall).
Neural Circuitry of Depressive Memory Bias
The storage and retrieval of emotionally charged memories rely on tightly regulated interactions between the amygdala, hippocampus, and prefrontal cortex:
- Amygdala Hyperactivity: The basolateral amygdala exhibits heightened baseline activation in depressed individuals. During emotional encoding, it hyperactivates, stamping strong emotional valence onto negative occurrences.
- Hippocampal Mis-contextualization: In a depressed brain, the structural changes caused by reduced neurogenesis hinder the hippocampus from properly contextualising memories. Negative experiences are stored as generalised, omnipresent threats rather than specific, time-bound events.
- Defective Top-Down Suppression: The ventromedial prefrontal cortex (vmPFC) normally acts as a brake on the amygdala during memory recall. In MDD, functional decoupling between the anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (dlPFC), and amygdala allows negative autobiographical memories to re-enter consciousness unimpeded.
Overgeneral Memory and Ruminative Cycles
Depressed patients frequently exhibit overgeneral autobiographical memory (OGM)—recalling categories of negative events (e.g., "people always fail me") rather than specific instances. OGM feeds directly into repetitive negative thinking and rumination, which continually reactivates stress pathways, exacerbating neurobiological damage and solidifying the depressive state.
Synaptic Plasticity and Cellular Stress
Synaptic plasticity, the capacity of neurons to strengthen or weaken synaptic connections over time via Long-Term Potentiation (LTP) and Long-Term Depression (LTD), forms the neurobiological substrate of learning, adaptation, and emotional resilience. Chronic cellular stress severely impairs synaptic plasticity, triggering structural remodelling that remodels neural circuits into rigid, maladaptive configurations.
Molecular Drivers of Cellular Stress
Cellular stress in the central nervous system originates from three main converging pathways:
- Excitotoxicity: Excess extracellular glutamate over-stimulates extrasynaptic N-methyl-D-aspartate (NMDA) receptors, leading to massive intracellular calcium (Ca+2) influx.
- Mitochondrial Dysfunction & ROS: Excessive Ca+2 overwhelms mitochondrial buffers, causing electron transport chain breakdown and generating harmful Reactive Oxygen Species (ROS).
- Neuroinflammation: Microglia transition into a pro-inflammatory M1 phenotype, releasing cytokines like TNF-α, IL-1β, and IL-6, which disrupt synaptic protein synthesis.
Structural Consequences: Spine Loss and Circuit Collapse
High ROS concentrations and chronic inflammatory signalling activate stress-responsive kinase pathways (such as JNK and p38 MAPK), initiating a structural cascade:
- Loss of Dendritic Spines: Postsynaptic density proteins (PSD-95) undergo degradation, causing thin, highly plastic "learning spines" to collapse into stable or non-functional stubs.
- Shift from LTP to LTD: High cellular stress inhibits the signalling networks necessary for LTP (e.g., CaMKII signalling), shifting the synaptic equilibrium toward Long-Term Depression (LTD). Synapses lose their strength, resulting in circuit-level disconnection across networks that govern reward, motivation, and executive function.
- Loss of Synaptic Density: Over time, this cumulative loss of dendritic spines reduces overall grey matter volume in the prefrontal cortex and hippocampus, explaining the persistent cognitive deficits seen in chronic stress and depressive conditions.
Latest Progress in Treatments of MDD
New treatment strategies are emerging that target the underlying neurobiological mechanisms of MDD.
KCNQ Channel Openers
Drugs like ezogabine, which target potassium channels, have shown promise in modulating brain cell activity and potentially alleviating symptoms like anhedonia by affecting the brain's reward centres.
FGFR1 Signalling
Research has uncovered an FGFR1–Notch–BDNF pathway in the hippocampus that can induce neurogenesis and produce antidepressant effects. Targeting a protein called Numb to restore this axis has reversed depressive phenotypes in studies.
NMDA Receptor Antagonists
NMDA receptor antagonists like esketamine and AXS-05 provide rapid relief for treatment-resistant depression and suicidal ideation by acting as circuit breakers" to restore brain function and boost synaptic growth.
α2A-Adrenergic Receptor Agonism
This approach is being explored as a stratified precision medicine treatment targeting the cognitive biotype of depression.
Conclusion
Major depressive disorder arises from a complex interplay of impaired neurogenesis, disrupted synaptic plasticity, and dysfunctional emotional memory processing. The failure of neural stem cells to mature, alongside reduced expression of plasticity-related genes, undermines the brain's capacity for stress adaptation and resilience.
The persistence of negative memories further reinforces the depressive state. Recent therapeutic advances, including KCNQ channel modulators, NMDA receptor antagonists, and strategies targeting neurogenic pathways, offer hope by directly addressing these mechanisms.
Future research should continue to stratify MDD by biological subtypes to enable more precise and effective treatments